Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M148,752Revenue $M43,255Net Margin (%)12.5Z-Score2.4
Enterprise Value $M163,030EPS $1.8Operating Margin %17.0F-Score6
P/E(ttm))28.0Cash Flow Per Share $0Pre-tax Margin (%)15.9Higher ROA y-yY
Price/Book2.210-y EBITDA Growth Rate %3.9Quick Ratio1.0Cash flow > EarningsY
Price/Sales3.55-y EBITDA Growth Rate %-2.0Current Ratio1.4Lower Leverage y-yN
Price/Cash Flow0y-y EBITDA Growth Rate %9.9ROA % (ttm)4.6Higher Current Ratio y-yN
Dividend Yield %3.4Insider Buy (3m)0ROE % (ttm)8.0Less Shares Outstanding y-yY
Payout Ratio %89.0Shares Outstanding M2,649ROI % (ttm)4.2Gross Margin Increase y-yN

Gurus Latest Trades with SNY

Number of guru portfolios checked: 56. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
SNYPRIMECAP Management 2014-06-30 Add0.03%$51.23 - $54.54
($53.08)
$ 56.737%Add 21.59%3,011,646
SNYScott Black 2014-06-30 Reduce-0.39%$51.23 - $54.54
($53.08)
$ 56.737%Reduce -27.57%178,985
SNYJohn Hussman 2014-06-30 Sold Out -0.09%$51.23 - $54.54
($53.08)
$ 56.737%Sold Out0
SNYScott Black 2014-03-31 Buy 1.4%$47.77 - $53.63
($50.64)
$ 56.7312%New holding, 247100 sh.247,100
SNYJames Barrow 2014-03-31 Add0.39%$47.77 - $53.63
($50.68)
$ 56.7312%Add 22.72%27,790,116
SNYCharles Brandes 2013-12-31 Add0.2%$48.75 - $54
($51.57)
$ 56.7310%Add 18.29%2,013,300
SNYMario Gabelli 2013-12-31 Reduce$48.75 - $54
($51.57)
$ 56.7310%Reduce -24.37%4,500
SNYJames Barrow 2013-09-30 Add1.29%$47.64 - $53.24
($50.87)
$ 56.7312%Add 312.86%21,466,988
SNYMario Gabelli 2013-09-30 Add$47.64 - $53.24
($50.87)
$ 56.7312%Add 32.22%5,950
SNYMario Gabelli 2013-06-30 Buy $49.77 - $55.64
($53.28)
$ 56.736%New holding, 4500 sh.4,500
SNYCharles Brandes 2013-06-30 Reduce-0.26%$49.77 - $55.64
($53.28)
$ 56.736%Reduce -20.35%1,713,266
SNYCharles Brandes 2012-09-30 Reduce-0.41%$36.81 - $44.6
($40.57)
$ 56.7340%Reduce -25.37%2,982,819
SNYDavid Dreman 2012-09-30 Sold Out -0.09%$36.81 - $44.6
($40.57)
$ 56.7340%Sold Out0
SNYJohn Hussman 2012-06-30 Add$33.4 - $39.06
($35.98)
$ 56.7358%Add 22.62%27,100
SNYPRIMECAP Management 2012-03-31 Add0.08%$35.32 - $38.92
($35.05)
$ 56.7362%Add 141.26%2,222,692
SNYJames Barrow 2011-12-31 Add0.08%$31.72 - $37.45
($34.48)
$ 56.7364%Add 26.83%4,501,475
SNYGeorge Soros 2011-12-31 Sold Out -0.11%$31.72 - $37.45
($34.48)
$ 56.7364%Sold Out0
SNYJames Barrow 2011-09-30 Add0.13%$31.5 - $40.08
($35.94)
$ 56.7358%Add 83.96%3,549,200
SNYGeorge Soros 2011-09-30 Buy 0.11%$31.5 - $40.08
($35.94)
$ 56.7358%New holding, 201400 sh.201,400
SNYDodge & Cox 2011-06-30 Add0.16%$35.68 - $40.58
($38.04)
$ 56.7349%Add 6.63%54,287,695
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

SNY is held by these Gurus:

Ticker Guru Name Portfolio Date* Current Shares % of Shares Outstanding % of Total Assets Managed Change from Last Holdings Holding History
SNY PRIMECAP Management 2014-06-303,011,6460.110.18+21.59%
SNY Charles Brandes 2014-06-302,182,3050.081.4+5.28%
SNY James Barrow 2014-06-3028,526,8021.082+2.65%
SNY Mario Gabelli 2014-06-304,50000
SNY Warren Buffett 2014-06-303,905,8750.150.19
SNY Dodge & Cox 2014-06-3043,549,9091.642.2-0.26%
SNY Jean-Marie Eveillard 2014-06-30608,5680.020.08-0.36%
SNY Scott Black 2014-06-30178,9850.011.4-27.57%
SNY John Hussman 2014-06-30000Sold Out
Premium Most recent portfolio changes are included for Premium Members only!


SNY: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Sanofi10% Owner 2014-03-25Buy344,448$66.88-15.49view
Sanofi10% Owner 2014-02-04Buy1,303,780$7.67636.9view

Press Releases about SNY :

    Quarterly/Annual Reports about SNY:

      News about SNY:

      Articles On GuruFocus.com
      Why Investing Internationally Can Help Your Portfolio Sep 12 2014 
      The MS Global Franchise Fund's Top Five Stocks Sep 10 2014 
      Guru Stocks at 52-Week Lows: CHL, TM, SNY, NVO, TSM Sep 02 2014 
      Sarah Ketterer’s Causeway International Value Fund Reports Top Five Aug 31 2014 
      The French Government Collapses…and French Stocks Rally. What Gives? Aug 26 2014 
      Guru Stocks at 52-Week Lows: CHL, TM, SNY, NVO, TSM Aug 23 2014 
      Sanofi Doesn´t Look Good in Absolute Valuation Method Aug 21 2014 
      How Sanofi's Growth Strategy Will Catapult Afrezza Into a Blockbuster Drug Aug 20 2014 
      Evaluating MannKind (MNKD) & Sanofi (SNY) Agreement for Afrezza Aug 15 2014 
      George Soros Reveals His Largest Stake Jul 23 2014 


      More From Other Websites
      Sanofi and MyoKardia Announce Groundbreaking Collaboration to Develop Targeted Therapies for... Sep 17 2014
      7:15 am Sanofi-Aventis and MyoKardia announced collaboration to develop targeted therapies for... Sep 17 2014
      Source Looks to Bring Europe ETF Success to the U.S. Sep 16 2014
      2 Solid Picks for a Weak Euro Sep 15 2014
      Today's Market Thorns, Roses, and All Time Highs... Sep 12 2014
      Sanofi Reports Data on Multiple Sclerosis Drug Lemtrada Sep 12 2014
      Eli Lilly/Boehringer's Insulin Biosimilar Gains EU Approval Sep 11 2014
      At Four Years, Treatment Effect Maintained in More Than Two-Thirds of Patients Who Received... Sep 11 2014
      The Market's Thorns, Roses, and All Time Highs... Sep 10 2014
      Receptos MS Drug Yields More Good Data; Stock Jumps Sep 10 2014
      Peregrine Pharmaceuticals' Q1 Loss Wider than Expected Sep 10 2014
      Genzyme Announces Launch of “Expression of Hope III” Program to Build Awareness of Lysosomal... Sep 10 2014
      Investment, Un-American Style Sep 10 2014
      FDA Approves Use of Menactra® Vaccine for Booster Immunization Against Potentially Deadly Disease Sep 08 2014
      Why Illumina (ILMN) Stock Is Gaining Today Sep 08 2014
      Genzyme to Feature Multiple Sclerosis Pipeline and Present New Data on Aubagio and Lemtrada at... Sep 08 2014
      [video] Regeneron Rises, Norwegian Cruises and CVS Health Quits the Habit Sep 04 2014
      Today's Market Thorns, Roses, and All Time Highs Sep 04 2014
      Amgen Seeks EU Approval for PCSK9 Inhibitor Evolocumab Sep 04 2014
      Sanofi Reports Positive Phase III Data on Dengue Vaccine Sep 03 2014

      Add Notes, Comments

      If you want to ask a question, or report a bug, please create a support ticket.

      User Comments

      No comment yet
      Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
      GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
      Free 7-day Trial
      FEEDBACK